A Study of Imlunestrant (LY3484356) in Healthy Women
Status:
Not yet recruiting
Trial end date:
2022-11-08
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when
administered orally on the levels of midazolam in the blood stream in healthy women of
non-childbearing potential. The study will also evaluate the safety and tolerability of
imlunestrant in healthy women of non-childbearing potential. This study will last up to
approximately 6 weeks for each participant including the screening period.